Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Accessibility StatementSkip Navigation HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfD ...

Core Insights - The article emphasizes the importance of conducting thorough due diligence before making any investment decisions, highlighting that investors should seek advice from financial professionals [3][4]. Group 1 - The author has a background in finance and accounting, with a focus on investments and financial analysis, which supports their insights into market trends [1]. - The author has experience managing investment portfolios, indicating a practical understanding of market dynamics [1]. - The article does not provide specific investment recommendations or endorsements for any companies mentioned [2][4].

Core Insights - Ginkgo Bioworks has launched Ginkgo Cloud Lab, an interface that allows researchers to utilize the company's autonomous lab infrastructure via a web browser [1] - The Cloud Lab operates on proprietary Reconfigurable Automation Carts (RACs), which integrate robotic arms, maglev transport tracks, and industrial software to create a flexible lab environment [1] - The initial launch features an AI-driven agent named EstiMate, enabling scientists to submit protocols in natural language and receive immediate compatibility assessments and pricing [1] - This initiative is part of Ginkgo's strategic shift in 2026 to transition all R&D services to its autonomous lab, Nebula, while phasing out traditional lab benches [1] Company Overview - Ginkgo Bioworks focuses on making biology easier to engineer, offering autonomous laboratories that enhance productivity by replacing manual lab work with robotics [1] - The company invites researchers from academia and global biopharmaceutical firms to test the Cloud Lab and submit protocols for development [1] - Ginkgo's autonomous lab services are also available through contract research services, enhancing its market offerings [1]

Core Insights - Ginkgo Bioworks is focusing on divesting its biosecurity business to redirect capital towards its autonomous labs strategy, which is expected to be a key growth area for the company in 2026 [1][6][7] Financial Performance - In Q4 2025, cell engineering revenue was $26 million, a 26% decline year-over-year, with full-year revenue at $133 million compared to $174 million in 2024 [5][9] - Cash burn improved significantly, falling to $171 million for 2025 from $383 million in 2024, with Q4 cash burn at $47 million, down from $55 million in Q4 2024 [16] - Total Adjusted EBITDA was -$36 million in Q4 2025, an improvement from -$57 million in Q4 2024, and for the full year, it was -$167 million compared to -$293 million in 2024 [15] Strategic Focus - The company plans to transition work from traditional lab setups to a single large autonomous lab in Boston, aiming to enhance efficiency and scalability [2][7] - Ginkgo aims to expand its autonomous lab capacity to 100 racks and integrate advanced AI technologies, such as GPT-5, into its operations [7][18] Future Guidance - For 2026, Ginkgo will not provide revenue guidance but will focus on cash burn, estimating it to be between $125 million and $150 million, reflecting ongoing investments in autonomous labs [17] - The company is prioritizing long-term investments over short-term revenue generation, emphasizing the importance of cash deployment in its strategic initiatives [17] Operational Developments - Ginkgo is actively working on enhancing its autonomous lab capabilities, including a new $47 million contract with the Department of Energy to build a 97-robot, 97-rack autonomous lab [25] - The company has hosted tours of its Nebula autonomous lab, which currently has over 50 racks, with plans to expand to 100 racks by mid-2026 [25]

Core Insights - Ginkgo Bioworks is experiencing a decline in stock price following its fourth-quarter and full-year 2025 financial report, as the company shifts focus towards investing in autonomous labs [1][2] Strategic Focus - The company is divesting its biosecurity business to a consortium of investors for a minority stake, which is expected to close in the first half of 2026, allowing Ginkgo to concentrate on its autonomous labs initiative [3] - This strategic pivot includes collaboration with the Department of Energy and OpenAI, emphasizing a focus on robotics and AI [2][4] Market Position and Analyst Views - Ginkgo's stock is currently trading 18.13% below its 20-day simple moving average (SMA) and 12.5% below its 100-day SMA, indicating a bearish trend, with shares down 54.5% over the past 12 months [7] - Analysts express concerns about low visibility and transparency, with William Blair reiterating an Underperform rating, while also noting that the divestment and renewed focus on core Cell Engineering are positive steps [5][6] Technical Analysis - The stock's Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at -0.05, suggesting bearish pressure [7][8] - Key resistance for the stock is identified at $8.50, with key support at $5.00 [10] Analyst Consensus - The stock carries a Hold Rating with an average price target of $169.73, although recent analyst actions include a downgrade from TD Cowen to a Buy with a lowered target of $12.00 [9]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Neurogene Inc. (NGNE) is up 34% at $26.42 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) is up 20% at $6.29 [3] - Applied Optoelectronics, Inc. (AAOI) is up 19% at $64.00 [3] - Caris Life Sciences, Inc. (CAI) is up 19% at $22.93 [3] - Block, Inc. (XYZ) is up 18% at $64.59 [3] - MARA Holdings, Inc. (MARA) is up 16% at $9.84 [3] - NCR Atleos Corporation (NATL) is up 14% at $48.13 [3] - Birchtech Corp. (BCHT) is up 12% at $2.70 [3] - The RealReal, Inc. (REAL) is up 11% at $13.80 [3] - Candel Therapeutics, Inc. (CADL) is up 10% at $5.68 [3] Premarket Losers - Duolingo, Inc. (DUOL) is down 24% at $88.30 [4] - Xponential Fitness, Inc. (XPOF) is down 23% at $6.16 [4] - Emergent BioSolutions Inc. (EBS) is down 22% at $8.58 [4] - Flutter Entertainment plc (FLUT) is down 14% at $105.85 [4] - Ginkgo Bioworks Holdings, Inc. (DNA) is down 14% at $8.27 [4] - Willdan Group, Inc. (WLDN) is down 12% at $104.63 [4] - Duos Technologies Group, Inc. (DUOT) is down 12% at $7.67 [4] - CoreWeave, Inc. (CRWV) is down 11% at $85.96 [4] - Zscaler, Inc. (ZS) is down 9% at $152.22 [4] - Progyny, Inc. (PGNY) is down 8% at $20.40 [4]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% compared to Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [15][16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, primarily due to customer program rationalization [15][16] - Total Adjusted EBITDA in Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, up from -$293 million in 2024 [20][21] - Cash burn in Q4 2025 was $47 million, down from $55 million in Q4 2024, and for the full year, it was $171 million, a 55% decrease from $383 million in 2024 [22][24] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 2025 compared to 2024 [17][20] - Cell engineering R&D expenses decreased 44% in Q4 2025 to $28 million, and for the full year, it decreased 42% to $159 million [18][19] Market Data and Key Metrics Changes - The company is focusing on the autonomous lab market, which is expected to transform biotechnology and is seen as a high-value area for investment [3][4] - The federal government and pharmaceutical companies are significant pools of research spending, with the NIH spending $40 billion annually on lab work [31][62] Company Strategy and Development Direction - The company plans to divest its biosecurity business to focus investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][11] - The strategy includes booking sales of autonomous labs to national labs and biopharma, with a notable $47 million deal with Pacific Northwest National Laboratory [6][31] - The company aims to improve cost efficiency while investing in AI robotics and software for autonomous labs, with a cash burn guidance of $125 million to $150 million for 2026 [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term orientation over short-term revenue targets [28][29] - The company highlighted the need for flexibility in lab operations and the potential for AI to enhance research productivity [59][60] Other Important Information - The company has made significant strides in reducing cash burn and controlling spending, setting a solid foundation for future investments [13][14] - The autonomous lab is positioned as a solution to save overhead costs and increase research productivity for biopharma and national labs [59][60] Q&A Session Summary Question: What is the outlook for revenue guidance in 2026? - The company will not provide revenue guidance for 2026, focusing instead on cash burn as a better reflection of ongoing services and investments in autonomous labs [24][25] Question: How does the company plan to commercialize autonomous labs? - The company plans to build autonomous labs for customers and offer cloud lab services, allowing scientists to outsource small lab work directly [61][62]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% from Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, primarily due to customer program rationalization [16] - Total Adjusted EBITDA in Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, up from -$293 million in 2024 [21][22] - Cash burn in Q4 2025 was $47 million, down from $55 million in Q4 2024, and for the full year, it was $171 million, a 55% decrease from $383 million in 2024 [23] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 compared to 2024 [18][21] - Cell engineering R&D expenses decreased 44% in Q4 2025 to $28 million, and for the full year, it decreased 42% to $159 million [19][20] Market Data and Key Metrics Changes - The company plans to focus on the autonomous lab market, which is expected to transform biotechnology and attract significant investment from both federal and private sectors [3][32] - The federal government, including the NIH, spends approximately $40 billion annually on lab work, indicating a substantial market opportunity for autonomous labs [32] Company Strategy and Development Direction - The company intends to divest its biosecurity business to concentrate investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][6] - The strategy includes systematic decommissioning of traditional lab setups to transition to a fully autonomous lab model, showcasing its potential to major pharmaceutical companies [5][30] - The company aims to book sales of autonomous labs to national labs, biopharma, and research universities, with a notable $47 million deal already secured [6][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term investment over short-term revenue targets [27][30] - The outlook for 2026 includes a focus on cost efficiency while investing in AI and robotics to enhance autonomous lab capabilities, with expected cash burn guidance set between $125 million and $150 million [24][25] Other Important Information - The company has made significant strides in reducing cash burn and improving cost efficiency, setting a solid foundation for future investments [26] - The autonomous lab initiative is positioned as a key technological foundation for the company over the next decade, with plans to expand lab capacity significantly [35][36] Q&A Session Summary Question: What is the company's long-term growth outlook? - The company is focusing on investing in autonomous labs, with a strategic shift away from short-term revenue targets to long-term capabilities and market leadership in this emerging field [27][30] Question: How does the company plan to commercialize autonomous labs? - The company will build autonomous labs for customers and offer cloud lab services, allowing scientists to engage with the technology before committing to larger investments [62][66]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% from Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [15][16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, with a significant reduction in cash burn from $383 million in 2024 to $171 million in 2025, a 55% decrease [13][22] - Total Adjusted EBITDA for Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, down from -$293 million in 2024 [20][21] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 2025 compared to 2024 [16][20] - Cell engineering R&D expenses decreased by 44% in Q4 2025 to $28 million, and for the full year, it decreased by 42% to $159 million, attributed to restructuring efforts [18][19] Market Data and Key Metrics Changes - The company is focusing on the autonomous lab market, which is expected to transform biotechnology, with significant interest from federal government spending and biopharma sectors [31][63] - The company plans to commercialize autonomous labs through direct sales and cloud lab services, targeting a market that includes $40 billion to $60 billion in pharma research spending [62][63] Company Strategy and Development Direction - The company intends to divest its biosecurity business to focus investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][11] - The strategy for 2026 includes cost efficiency while investing in AI robotics and software to enhance autonomous labs, with a cash burn guidance of $125 million to $150 million [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term investment over short-term revenue targets [27][29] - The company highlighted the successful collaboration with OpenAI, showcasing advancements in AI-driven scientific experimentation [30] Other Important Information - The company has made significant strides in reducing cash burn and improving operational efficiency, setting a solid foundation for future investments in autonomous labs [14][22] - The company is actively engaging with top pharma customers and government entities, indicating strong market interest in its solutions [67] Q&A Session Summary Question: What is the outlook for revenue guidance in 2026? - The company will not provide revenue guidance for 2026, focusing instead on cash burn as a better reflection of ongoing services and investments in autonomous labs [23] Question: How does the company plan to commercialize autonomous labs? - The company plans to build autonomous labs for customers and offer cloud lab services, allowing scientists to engage with the technology before committing to larger investments [62][66]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________ FORM 10-K ______________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40097 _______________ ...